Hospital Universitario Clinico San Cecilio — Clinical Trial Site

153 Registered trials

68 Currently recruiting

Organisation

Hospital Universitario Clinico San Cecilio

Location

Granada, Spain

Identifier

ORG-100033024

Address

Avenida Del Conocimiento S/n, Poligono Industrial De Ciencias De La Salud, 18016, Spain

Departments

1214: Oncología Médica
2805:Dermatología
3135: Cardiología
40885: Dermatología
6072: Dermatology
Allergology
Allergy
Angiology and Vascular Sugery
Autoimmune diseases
Cardiología
Cardiology
Dermatologia
Dermatology
Endocrinology and Nutrition service
Enfermedades autoinmunes
Enfermedades Autoinmunes Sistémicas
Gynecology and Obstetrics
Heart Failure and Pulmonary Hypertension Unit
Hospital Universitario San Cecilio
Infectious
infectious diseases
Internal medicine
Medical Oncology
Medicina Nuclear
N/A
Neurology
Obstetricia
Obstetrician and Gynecologist
Oftalmologia
Oncolgy
Oncología
Oncología Médica
Oncology
Oncology Service
Radiology
Rheumatology
Rheumatology Service
Servicio de Angiología y Cirugía vascular
Servicio de Cardiologia
Servicio de Dermatología
Servicio de Endocrinología
Servicio de Enfermedades Infecciosas
Servicio de Oftalmología
Servicio de Oncologia
Servicio de Oncología Médica
Systemic Autoimmune Diseases Service
Systemic autoimmune diseases unit
UCG Enfermedades Infecciosas, Microbiología y Medicina preventiva
Unidad de Enfermedades Autoinmunes
Urología
Urology

Clinical trials at this site (153)

Search interface

Biomarker analysis in patients with metastatic breast cancer treated with sacituzumab govitecan. Recruiting

2023-505385-28-00 male or pre/post-menopausal women age ≥ 18 years with l 4 2023-10-19
Aspirin versus placebo in twin pregnancies for preeclampsia prevention: A multicentre, randomised, double-blind, placebo-controlled trial (A… Recruiting

2023-503698-40-00 Preeclampsia 5 2023-03-23
EARLY treatment with Candesartan vs Placebo in asymptomatic GENEtic carriers of Dilated Cardiomyopathy (EARLY-GENE trial) Recruiting

2023-507029-40-00 Genetic carriers of dilated cardiomyopathy causing vari 5 2022-05-09
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or… Recruiting

2023-507149-27-00 Chemotherapy-induced Thrombocytopenia in Adult subjects 5 2019-11-04
LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES Recruiting

2022-502706-33-00 Patients with invasive breast cancer in early stages 6 2018-01-10
Ribociclib in combination with endocrine therapy in patients with “estrogen receptor-positive and HER2-negative” breast cancer with high ris… Ended

2023-508827-10-00 Patients with primary operable stage II, grade 2 or 3, 4 2025-10-13
"Neoadjuvant phase II study of pembrolizumab and carboplatin plus paclitaxel for stage I triple-negative breast cancer (The TELESCOPE study)… Ended

2024-513511-27-00 HR-negative/HER2-negative resectable stage I TNBC. 4 2025-05-29
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended

2024-512925-95-00 Advanced/Metastatic Breast Cancer 5 2025-05-16
A Multicenter, Open-Label, Single-Arm, Phase II Trial Exploring the Maintenance of Trastuzumab and Pertuzumab Following Trastuzumab Deruxtec… Ended

2023-507306-13-00 HER2-positive unresectable locally recurrent or metasta 4 2025-04-13
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women with Breast Cancer Who Are Having Hormone Therapy Ended

2024-510719-31-00 Moderate to Severe Vasomotor Symptoms (VMS) 5 2025-01-24
Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 2 (STOP-PN2) Ended

2024-511881-35-00 Prurigo Nodularis 5 2024-12-17
A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in… Ended

2023-508096-36-00 atopic dermatitis 5 2024-10-30
REIMAGINE 5: A research study to see how much CagriSema (1.0 mg once weekly) lowers blood sugar and body weight compared to tirzepatide (5 m… Ended

2023-509600-15-00 Type 2 Diabetes 5 2024-10-18
Clinical trial to assess the efficacy and safety of a vaccine for grasses and olive tree allergy Ended

2024-514525-34-00 Aetiological treatment of moderate-severe intermitent o 5 2024-08-18
Phase 3 Study of ALXN1850 versus Placebo in Adolescent and Adult Participants with HPP who have not previously been treated with Asfotase Al… Ended

2023-505673-32-00 Hypophosphatasia 5 2024-08-05
Allogeneic Tissue Engineering (Nanostructured Artificial Human Cornea) in Patients With Corneal Trophic Ulcers in Advanced Stages, Refractor… Ended

2024-515481-13-00 Corneal trophic ulcers refractory to conventional treat 7 2024-07-05
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Ended

2023-508235-31-00 Atopic Dermatitis 5 2024-06-17
Phase II Study of Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-Low Breast Cancer Patients Presenting with Newly Diagnosed or Progressing… Ended

2023-506702-39-00 HER2-low breast cancer presenting with newly diagnosed 4 2024-06-05
A trial to learn if taking osimertinib before and after chemotherapy and radiation therapy is safe and works in adults with non-small cell … Ended

2023-507798-16-00 Unresectable Non-small Cell Lung Cancer 4 2024-04-16
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit… Ended

2023-505928-59-00 Triple Negative or Hormone Receptor low/HER2-negative B 5 2024-04-15
A Phase 3 Study of DB-1303 vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer Ended

2023-507333-17-00 HER2-low, Hormone Receptor Positive, Metastatic Breast 5 2024-04-15
A study to assess adverse events and effectiveness of upadacitinib oral tablets in adult and adolescent participants with vitiligo. Ended

2023-506195-27-00 non-segmental vitiligo 5 2024-04-05
A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity Ended

2022-502442-27-00 Obesity 5 2024-01-08
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatm… Ended

2023-505122-34-00 Plaque Psoriasis 5 2023-12-05